In 2023, Christopher A. Viehbacher earned $3.98M in total compensation at Biogen, including $1.60M salary and $2.38M bonus. Most recently acquired 2,195 shares in May 2024. Currently holds stock worth $13.67M. 3+ years at the helm of Biogen.
Compensation History
Annual executive compensation data for Christopher A. Viehbacher, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$3.98M
Salary
$1.60M
Bonus
$2.38M
Other
$0.00
Salary
$1.60MBoard Justification
The compensation philosophy is to reward executives for the creation of long-term stockholder value, with a focus on performance-based compensation that is competitive with peer groups to attract and retain leaders.
Bonus
$2.38MBoard Justification
The annual bonus for Mr. Viehbacher was based on the achievement of company performance goals and individual performance goals, with a company multiplier of 99% and an individual multiplier of 100%.
Other Compensation
$0.00Board Justification
No additional compensation was reported for Mr. Viehbacher in 2023.
Restricted Stock
Board Justification
No stock was granted or vested in 2023 as Mr. Viehbacher was not eligible for LTI grants in 2023.
Performance Metrics
The performance metrics for Mr. Viehbacher's compensation included company financial performance and individual performance goals.
Christopher A. Viehbacher
CEO of Biogen
Education
B. Comm from Queen's University
Field of Expertise
Healthcare & Life Sciences - Healthcare
Sector of Economy
Healthcare
Born
January 1, 1960 - 65 years ago
CEO of Biogen for
3 years 0 months (Nov 2022 - Present)
Previous Experience
Managing Partner at Gurnet Point Capital, former Global CEO at Sanofi
Other Biogen CEOs
Holdings
Track Christopher A. Viehbacher's stock holdings and portfolio value over time.
Insider Trading
Christopher A. Viehbacher's recent stock transactions, purchases, and sales filed with the SEC.
2,195 shares
RVTY
May 1, 2024
Received
1,738 shares
RVTY
May 15, 2023
Received
10,594 shares
BIIB
Jan 19, 2022
Received
16,343 shares
BIIB
Jan 27, 2021
Received
$748.05K
BIIB at $241.31/share
Nov 30, 2020
Purchase
$1.01M
BIIB at $231.48/share
May 1, 2019
Purchase
$250.03K
BIIB at $320.55/share
Dec 29, 2017
Purchase
$380.43K
BIIB at $271.35/share
May 1, 2017
Purchase
$380.42K
BIIB at $285.39/share
Feb 27, 2017
Purchase
Rivals
Compare Christopher A. Viehbacher with competitor CEOs and industry peers.
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M
Brett P. Monia, Ph.D.
Founder and CEO of Ionis Pharmaceuticals
2023 Compensation
Stock
$430.00K
Salary
$650.00K
Bonus
$300.00K
Other
$50.00K
Total Holdings
$6.01M